{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T11:24:18Z","timestamp":1763724258583,"version":"3.37.3"},"reference-count":34,"publisher":"Georg Thieme Verlag KG","issue":"06","funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2012]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Despite the need for effective and safe thromboprophylactic drugs for patients with renal impairment, clinical trial data on anticoagulant agents are limited in this population. The study aim was to assess in the real-world setting the use of the once-daily 1.5 mg reduced dosage regimen of fondaparinux available for this context. In this prospective cohort study, patients with a creatinine clearance (CrCl) of 20\u201350 ml\/ minute, undergoing total hip (THR) or knee (TKR) replacement or hip fracture surgery (HFS) received fondaparinux thromboprophylaxis. Main clinical outcomes were bleeding (major\/clinically relevant nonmajor), symptomatic venous thromboembolism (VTE) and death. Overall, 442 patients (353 women; median age: 82 years; 39.4% in ASA class \u22653; mean \u00b1 SD CrCl: 39.0 \u00b1 8.0 ml\/minute; 78% with additional risk factors for bleeding), undergoing THR (43.7%), TKR (27.6%), or HFS (28.7%) received fondaparinux 1.5 mg for a mean \u00b1 SD duration of 16.0 \u00b1 12.5 days. At postoperative day 10, the rates (95% confidence interval) of major bleeding, clinically relevant bleeding and symptomatic VTE were 4.5% (2.8\u20136.9), 0.5% (0.1\u20131.6) and 0.5% (0.05\u20131.62), respectively; no fatal bleeding, bleeding into a critical organ, pulmonary embolism or proximal deep-vein thrombosis occurred. Corresponding rates at one month were 5.2%, 0.7% and 0.7%. One-month mortality was 2.3% (0.9\u20133.6). This large clinical prospective study provides for the first time, under conditions reflecting \u201creal-world\u201d routine clinical practice, data on the bleeding and VTE risks of thromboprophylaxis with fondaparinux 1.5 mg after major orthopaedic surgery in renally impaired patients. It shows that these patients constitute a very elderly and fragile population.<\/jats:p><jats:p>ClinicalTrials.gov number, NCT00555438<\/jats:p>","DOI":"10.1160\/th11-09-0640","type":"journal-article","created":{"date-parts":[[2012,4,4]],"date-time":"2012-04-04T16:14:58Z","timestamp":1333556098000},"page":"1151-1160","source":"Crossref","is-referenced-by-count":25,"title":["Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery"],"prefix":"10.1160","volume":"107","author":[{"given":"Patrick","family":"Mismetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles-Marc","family":"Samama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Rosencher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Vielpeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Deygas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Presles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvy","family":"Laporte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for The PROPICE Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2017,11,29]]},"reference":[{"key":"10.1160\/TH11-09-0640-1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.04.028"},{"key":"10.1160\/TH11-09-0640-2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0656"},{"key":"10.1160\/TH11-09-0640-3","doi-asserted-by":"crossref","unstructured":"SFAR 2005. Pr\u00e9vention de la maladie thromboembolique veineuse p\u00e9riop\u00e9ratoire et obst\u00e9tricale. Recommandations pour la pratique clinique. Available at: http:\/\/www.sfar.org\/_docs\/articles\/209-RPC%20MVTE.pdf. Accessed May 24, 2011.","DOI":"10.1016\/j.annfar.2005.06.012"},{"key":"10.1160\/TH11-09-0640-4","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0689"},{"key":"10.1160\/TH11-09-0640-5","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(91)90141-I"},{"key":"10.1160\/TH11-09-0640-6","doi-asserted-by":"publisher","DOI":"10.1159\/000186641"},{"key":"10.1160\/TH11-09-0640-7","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(02)00031-2"},{"key":"10.1160\/TH11-09-0640-8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2005.09.009"},{"key":"10.1160\/TH11-09-0640-9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.5414\/CPP44455","volume":"44","author":"St\u00f6be","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1160\/TH11-09-0640-10","first-page":"976","volume":"91","author":"Tincani","year":"2006","journal-title":"Haematologica"},{"key":"10.1160\/TH11-09-0640-11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1160\/TH06-09-0513","volume":"97","author":"Mah\u00e9","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH11-09-0640-12","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200724010-00005"},{"key":"10.1160\/TH11-09-0640-13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02920.x"},{"key":"10.1160\/TH11-09-0640-14","unstructured":"Arixtra. Fondaparinux sodium. Summary of Product Characteristics. European Medicines Agency. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000403\/WC500027746.pdf. Accessed May 24, 2011."},{"key":"10.1160\/TH11-09-0640-15","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e328323da86"},{"key":"10.1160\/TH11-09-0640-16","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-007-0360-7"},{"key":"10.1160\/TH11-09-0640-17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103013440901"},{"key":"10.1160\/TH11-09-0640-18","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.16.1833"},{"key":"10.1160\/TH11-09-0640-19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800374"},{"key":"10.1160\/TH11-09-0640-20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa076016"},{"key":"10.1160\/TH11-09-0640-21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61445-7"},{"key":"10.1160\/TH11-09-0640-22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02748.x"},{"key":"10.1160\/TH11-09-0640-23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01545.x"},{"key":"10.1160\/TH11-09-0640-24","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2005.04.018"},{"key":"10.1160\/TH11-09-0640-25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02779.x"},{"key":"10.1160\/TH11-09-0640-26","doi-asserted-by":"publisher","DOI":"10.1213\/01.ane.0000287677.95626.60"},{"key":"10.1160\/TH11-09-0640-27","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2010.03.021"},{"key":"10.1160\/TH11-09-0640-28","unstructured":"Pradaxa (dabigatran etexilate). EMEA\/174363\/2008. London, 2008. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/000829\/WC500041062.pdf. Assessed May 24, 2011."},{"key":"10.1160\/TH11-09-0640-29","unstructured":"Xarelto (rivaroxaban). EMEA\/543519\/2008. London, 2008. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/000944\/WC500057122.pdf. Accessed May 24, 2011."},{"key":"10.1160\/TH11-09-0640-30","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0674"},{"key":"10.1160\/TH11-09-0640-31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03328.x"},{"key":"10.1160\/TH11-09-0640-32","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/s-0037-1613491","volume":"90","author":"Turpie","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH11-09-0640-33","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2005.05.023"},{"key":"10.1160\/TH11-09-0640-34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011100"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH11-09-0640.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T05:29:39Z","timestamp":1641965379000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH11-09-0640"}},"subtitle":["A real-world, prospective, multicentre, cohort study"],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":34,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2017,11,29]]},"published-print":{"date-parts":[[2012,6]]}},"URL":"https:\/\/doi.org\/10.1160\/th11-09-0640","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"type":"print","value":"0340-6245"},{"type":"electronic","value":"2567-689X"}],"subject":[],"published":{"date-parts":[[2012]]}}}